Clarity Pharmaceuticals Partners with Theragenics for Copper-64 Supply Agreement
In a groundbreaking development for cancer diagnostics and treatment, Clarity Pharmaceuticals (ASX: CU6), a prominent clinical-stage radiopharmaceutical firm, has recently formalized a large-scale Manufacturing Supply Agreement with Theragenics. This initiative aims to ensure a reliable supply of copper-64, a critical radioisotope used in advanced cancer imaging and therapy.
This agreement specifically involves Theragenics' expansive 134,000 square foot production facility located near Atlanta, Georgia, which is equipped with a sophisticated fleet of 14 cyclotrons. Such infrastructure positions Theragenics as a key player for centralized copper-64 production in anticipation of Clarity’s upcoming commercial launch of 64Cu-SAR-bisPSMA. The launch is contingent upon the successful completion of Clarity’s Phase III clinical trials, namely AMPLIFY and CLARIFY, as well as receiving approval from the U.S. Food and Drug Administration (FDA).
Theragenics boasts a rich legacy of over 40 years in the realm of radiometal production and has excelled in the manufacturing of radioisotopes for medical applications. Their expertise, coupled with the capacity to produce approximately 100 Ci (3.7 TBq) of copper-64 per day per cyclotron, translates into an impressive output of around 2,000 patient doses daily, accommodating the growing demand for precise and timely cancer diagnostics. Each copper-64 dose has a half-life of 12.7 hours, allowing for a longer shelf-life of up to 48 hours. This extended shelf-life provides critical flexibility in scheduling and administering patient treatments, overcoming limitations presented by shorter-lived radionuclides commonly utilized in current radiodiagnostic processes.
The partnership with Theragenics signifies an expansion of Clarity’s existing manufacturing network by complementing existing agreements with SpectronRx and Nusano. The goal is to secure a robust supply chain capable of meeting extensive oncology market needs efficiently and effectively. In his remarks, Mark Pugh, CEO of Theragenics, emphasized the mutual passion for enhancing patient care through groundbreaking radiopharmaceutical solutions and expressed enthusiasm for partnering with Clarity. Having recognized the increasing excitement among oncologists regarding the potential of 64Cu-SAR-bisPSMA, he sees Clarity as the ideal collaborator to capitalize on the growing contract manufacturing opportunities in the isotope market.
Dr. Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, articulated the company’s commitment to driving its innovative cancer treatment forward. With final preparations underway as both companies collaborate, he stated, "Clarity is closer than ever to the commercialization of 64Cu-SAR-bisPSMA, buoyed by favorable results observed in head-to-head clinical trials. Building a secure, reliable supply chain is essential for our anticipated market launch and to meet future demands as we secure FDA approval. It's crucial that we work closely with all stakeholders involved — from vendors to regulatory agencies — to bring this valuable treatment to patients rapidly and effectively."
This collaboration not only indicates a significant stride towards enhancing cancer treatment solutions but also illustrates Clarity Pharmaceuticals' proactive approach in setting the stage for future expansions in the oncology sector. The Manufacturing Supply Agreement became effective on March 25, 2026, underscoring the shared vision of both companies toward pioneering the next generation of cancer diagnostics and treatments.
Looking ahead, both Clarity and Theragenics are united in their vision to revolutionize the realm of radiopharmaceuticals as they move towards making copper-64 accessible to healthcare providers across the United States. As progress continues, the landscape of cancer diagnostics is poised to transform remarkably, providing hope and enhanced outcomes for patients battling this pervasive disease.
This agreement specifically involves Theragenics' expansive 134,000 square foot production facility located near Atlanta, Georgia, which is equipped with a sophisticated fleet of 14 cyclotrons. Such infrastructure positions Theragenics as a key player for centralized copper-64 production in anticipation of Clarity’s upcoming commercial launch of 64Cu-SAR-bisPSMA. The launch is contingent upon the successful completion of Clarity’s Phase III clinical trials, namely AMPLIFY and CLARIFY, as well as receiving approval from the U.S. Food and Drug Administration (FDA).
Theragenics boasts a rich legacy of over 40 years in the realm of radiometal production and has excelled in the manufacturing of radioisotopes for medical applications. Their expertise, coupled with the capacity to produce approximately 100 Ci (3.7 TBq) of copper-64 per day per cyclotron, translates into an impressive output of around 2,000 patient doses daily, accommodating the growing demand for precise and timely cancer diagnostics. Each copper-64 dose has a half-life of 12.7 hours, allowing for a longer shelf-life of up to 48 hours. This extended shelf-life provides critical flexibility in scheduling and administering patient treatments, overcoming limitations presented by shorter-lived radionuclides commonly utilized in current radiodiagnostic processes.
The partnership with Theragenics signifies an expansion of Clarity’s existing manufacturing network by complementing existing agreements with SpectronRx and Nusano. The goal is to secure a robust supply chain capable of meeting extensive oncology market needs efficiently and effectively. In his remarks, Mark Pugh, CEO of Theragenics, emphasized the mutual passion for enhancing patient care through groundbreaking radiopharmaceutical solutions and expressed enthusiasm for partnering with Clarity. Having recognized the increasing excitement among oncologists regarding the potential of 64Cu-SAR-bisPSMA, he sees Clarity as the ideal collaborator to capitalize on the growing contract manufacturing opportunities in the isotope market.
Dr. Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, articulated the company’s commitment to driving its innovative cancer treatment forward. With final preparations underway as both companies collaborate, he stated, "Clarity is closer than ever to the commercialization of 64Cu-SAR-bisPSMA, buoyed by favorable results observed in head-to-head clinical trials. Building a secure, reliable supply chain is essential for our anticipated market launch and to meet future demands as we secure FDA approval. It's crucial that we work closely with all stakeholders involved — from vendors to regulatory agencies — to bring this valuable treatment to patients rapidly and effectively."
This collaboration not only indicates a significant stride towards enhancing cancer treatment solutions but also illustrates Clarity Pharmaceuticals' proactive approach in setting the stage for future expansions in the oncology sector. The Manufacturing Supply Agreement became effective on March 25, 2026, underscoring the shared vision of both companies toward pioneering the next generation of cancer diagnostics and treatments.
Looking ahead, both Clarity and Theragenics are united in their vision to revolutionize the realm of radiopharmaceuticals as they move towards making copper-64 accessible to healthcare providers across the United States. As progress continues, the landscape of cancer diagnostics is poised to transform remarkably, providing hope and enhanced outcomes for patients battling this pervasive disease.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.